Journal of Pediatric Gastroenterology & Nutrition:
Performance of the AST-to-Platelet Ratio Index as a Noninvasive Marker of Fibrosis in Pediatric Patients With Chronic Viral Hepatitis
McGoogan, Katherine E*; Smith, P Brian†; Choi, Steve S||; Berman, Wallace‡; Jhaveri, Ravi§
*Department of Pediatrics, USA
†Divisions of Quantitative Sciences, USA
§Infectious Diseases, USA
||Department of Medicine, Division of Gastroenterology, Duke University Medical Center, Durham, NC. At the time of writing, Dr McGoogan was in the DUMC Department of Pediatrics; she is now in the Department of Pediatrics, Division of Gastroenterology, University of Florida, Gainesville, USA.
Received 14 January, 2009
Accepted 11 May, 2009
Address correspondence and reprint requests to Ravi Jhaveri, MD, Division of Pediatric Infectious Diseases, DUMC Box 3499, Duke University Medical Center, Durham, NC 27710 (e-mail: email@example.com).
The authors report no conflicts of interest.
We investigated the performance of aspartate aminotransferase to platelet ratio index (APRI) as a noninvasive marker of fibrosis and cirrhosis in children with chronic viral hepatitis. All of the patients 0 to 20 years old with chronic hepatitis B or C presenting at a tertiary medical center from 1992 to 2008 were identified. Thirty-six patients were evaluated with 48 biopsy results. The areas under the receiver operating characteristic curve were 0.71 for fibrosis and 0.52 for cirrhosis. When examining subgroups, the APRI performed better in older patients and in those with vertically transmitted hepatitis C virus. Further research into APRI and the other noninvasive markers of fibrosis in children with chronic viral hepatitis is warranted.
Chronic viral hepatitis remains a relatively rare but significant problem among pediatric patients. Current prevalence estimates of hepatitis C among pediatric patients are 0.2% to 0.4% with an estimated cost of $160 to $400 million for the 2010 to 2019 decade (1,2). The incidence of acute hepatitis B has declined rapidly in the United States because of vaccination, but neonates and young children are much more likely than adults to progress to chronic hepatitis B infection (3–6). The optimal management of children with chronic viral hepatitis is still being investigated (7).
For patients with chronic viral hepatitis, liver biopsy is the standard for evaluation of disease severity and progression. Unlike adults who undergo liver biopsy as outpatients with only local anesthesia, pediatric patients routinely require general anesthesia and at least an overnight hospital stay postprocedure to observe them for potential complications. Although the overall complication rate of percutaneous liver biopsy is low, significant hemorrhage leading to death can occur (8,9). Noninvasive markers of fibrosis in adults with chronic hepatitis B or hepatitis C have been evaluated with some success, but these markers may have an even greater value in children (10–15).
The use of the aspartate aminotransferase (AST) to platelet ratio index (APRI) as a correlate of disease progression is present in the liver pathobiology. AST levels rise with the progression of liver disease as a likely result of direct hepatocellular damage and membrane leak, although they may normalize in patients with compensated cirrhosis (16,17). Platelet counts decrease with progression of liver disease and the resultant changes in splenic blood flow (17–19). These test results are collected as part of the standard of care for children with liver disease and thus would not result in added cost or effort. Our goal was to investigate the performance of APRI as a potential noninvasive marker of fibrosis in children chronically infected with hepatitis B or C.
MATERIALS AND METHODS
This study was reviewed and approved by the Duke University institutional review board. All of the patients ages 0 to 20 years with a diagnosis of chronic hepatitis B or C presenting at a tertiary medical center from January 1992 until January 2008 were evaluated. Patients were identified using several methods: a search of inpatient/outpatient hospital databases for International Classification of Disease, Ninth Revision, diagnosis codes related to hepatitis B or C (070.2, 070.3, 070.4, 070.5, 070.7, 070.9, V02.61, and V02.62) and records obtained from the clinical laboratories for all of the pediatric patients with a positive result for hepatitis C virus (HCV)-RNA, HCV antibody test, hepatitis B surface antigen, or hepatitis B virus (HBV)-DNA. Using the compiled roster of patients, the diagnosis of chronic HBV or HCV infection was confirmed by chart review. Dictated pathology reports of liver biopsies performed on any of these patients were then evaluated to determine the fibrosis score using the METAVIR system (fibrosis stage I–IV). Laboratory data within 4 months of liver biopsy was used for the calculations. AST was measured using the Vitros system (USA); enzymatic rate reaction and platelets were measured using electronic impedance (resistance) or fluorescent flow cytometry. An AST value of 40 was used as the upper limit of normal (ULN). APRI was calculated with the following formula:
Equation (Uncited)Image Tools
Patients were excluded for incomplete data or if they were recent liver transplant recipients. Fibrosis was defined as a METAVIR score of II or III and cirrhosis was defined as a score of IV on biopsy. Six patients had a dictated pathology report that did not assign a METAVIR score. In those cases, 1 investigator (S.S.C.), blinded to the patient's historical data, used the elements of the report to assign a METAVIR score range. In our analysis, we conducted separate analyses using the higher and lower scores and they did not influence the performance of the test. We used the lower scores and proceeded as described below.
We evaluated the value of the APRI in predicting liver fibrosis or cirrhosis by using nonparametric methods to produce receiver operating characteristic (ROC) curves. The main analysis was limited to the first reported biopsy results of the patient. The sensitivity, specificity, positive predictive value, negative predictive value, positive likelihood ratio, and negative likelihood ratio were calculated for APRI of 0.5 and 1.5, respectively. We conducted the analysis with STATA 10 (StataCorp, College Station, Texas).
We identified 36 patients with complete data who had a total of 48 biopsies performed. The average age of the patients was 11.6 years (range 1–20 years), 50% (18/36) of the patients were boys, and HCV-infected patients made up 69% (25/36) of the cohort. The vast majority of the patients were treatment naïve at the time of biopsy. Among the children infected with HCV, 7 had vertical transmission, 9 had transfusion transmission, and 9 had an unknown route. On average, children with vertical transmission were younger than those with transfusion transmission (8.0 vs 14.9 years) and had lower fibrosis scores (1.1 vs 1.6, respectively).
The median APRI was 0.44 (interquartile range 0.24–0.97) and 0.33 (interquartile range 0.20–0.44) among the patients with hepatitis B and C, respectively (P = 0.33). The median fibrosis score was 2 (1,2) and 1 (1,2) among the patients with hepatitis B and C, respectively (P = 0.22).
ROC curves were generated for the entire cohort, as well as the following subgroups: hepatitis B versus hepatitis C infected, and age younger than 13 years and 13 years old or older. The area under the ROC (area under curve [AUC]) was 0.71 for identifying patients with fibrosis and 0.52 for identifying patients with cirrhosis on liver biopsy. Table 1 summarizes the performance and 95% confidence intervals of each subgroup. APRI performed reasonably well when predicting fibrosis in patients with HBV and HCV (0.64 and 0.75, respectively) and 0.65 in children older than 13 years of age. Within the HCV-infected patient group, the performance was better in predicting fibrosis among those patients with vertically transmitted infection compared with transfusion-transmitted infection (1.00 vs 0.53). When all of the biopsy results were included in a separate analysis (n = 48), ROC values were 0.63 and 0.47 for fibrosis and cirrhosis, respectively.
The sensitivity, specificity, positive predictive value, negative predictive value, positive likelihood ratio, and negative likelihood ratios for APRI cutoff values of 0.5 and 1.5 for predicting fibrosis or cirrhosis are given in Table 2.
The APRI was designed to be a convenient marker of fibrosis because it incorporates laboratory data that are routinely obtained as the standard of care. Initial studies showed that it performed well in predicting fibrosis and cirrhosis in both a training and validation set of adults with chronic HCV infection (11,13,15).
There have been few studies in children. Our study found that the APRI was moderately useful in predicting significant fibrosis, where it could be a substitute for liver biopsy with AUC of 0.71. This is in line with the findings of Lebensztejn et al (12) in their study of children with hepatitis B that found an AUC of 0.74 in predicting advanced liver fibrosis. de Ledinghen et al (10) studied APRI in comparison with fibrosure and fibroscan results and found an AUC of 0.73 for predicting cirrhosis in children with various chronic liver diseases. This study did not generate ROC values for APRI and fibrosis and they had only 2 children with hepatitis B or C, so direct comparisons between our study and their study would be difficult.
The finding that APRI predicted fibrosis slightly better in patients older than 13 years is worth further discussion. When examining this closely, this may reflect some bias in the analysis. Because we had several patients with multiple biopsies, we used 1 data point per patient and chose the most recent value. Because some of these patients had disease progression, it may reflect some sampling bias. The fact that APRI performed comparatively well in the subset of HCV patients with vertically transmitted disease is interesting, but this may also reflect sampling bias in a small subpopulation.
The APRI is inherently limited by the use of a standard upper limit of normal value. Past studies have shown that many pediatric patients have normal AST values of 15 to 20, but an AST of 40 would likely generate a low APRI value despite the fact that this value would be twice that of a patient's normal value (20). Unfortunately, we, as clinicians taking care of these patients, are rarely provided with an AST value that precedes their viral hepatitis.
Another limitation of the APRI that has been fairly consistent is the lack of sensitivity for mild-to-moderate fibrosis. This is logically based on the pathobiology involved. AST levels rise and platelet counts fall relatively later in the disease progression, and the data in children with HBV and HCV reinforce this point (17,21–28). In patients with compensated cirrhosis and with normal AST values, the test would also be a poor predictor of significant fibrosis.
This study is limited by its small sample size, retrospective nature, and analysis of patients from a single center. Although some of the laboratory data were obtained as far as 4 months from the biopsy date, Wai et al (15) have validated the APRI using laboratory data up to 4 months from the biopsy date. Given the duration of 16 years of patient records, the study is also limited by intra- and interobserver variability of pathologists examining biopsy samples. We did not have the resources to reexamine all of the biopsies to limit this variability. There was also no consideration of inflammatory activity. We chose to focus on the ability of APRI to predict fibrosis and cirrhosis alone, but we recognized that in certain scenarios (HBV infection), inflammatory activity is an important factor to consider. The method of AST measurement changed at our institution in April 2008. Despite a listed ULN value of 60 for adults, we used a value of 40 for this pediatric study in consonance with the historical values (20). This change in methodology may alter the value of the APRI index going forward.
A validated noninvasive marker of fibrosis would be useful in pediatric patients. Such a marker could help to guide the clinicians as to whom to treat and serve as a longitudinal marker of treatment efficacy without the need for repeated liver biopsies. The results of this study indicate that APRI is not such a marker except perhaps in a defined group of patients. Further research is needed in this area to identify noninvasive markers that are reliable and feasible for use in pediatric patients.
The authors would like to acknowledge the following individuals who contributed to the design and execution of this study: Jeff Ferranti, MD; Stanley Mirrett, MS; Kim Hanson, MD; John Daly, MD; Bruce Lobaugh, PhD; and Mary Ann Dotson, CLS.
1. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341:556–562.
2. Jhaveri R, Grant W, Kauf TL, et al. The burden of hepatitis C virus infection in children: estimated direct medical costs over a 10-year period. J Pediatr 2006; 148:353–358.
3. Acute hepatitis B among children and adolescents–United States, 1990–2002. MMWR Morb Mortal Wkly Rep 2004;53:1015–8.
4. Okada K, Kamiyama I, Inomata M, et al. e Antigen and anti-e in the serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus to their infants. N Engl J Med 1976; 294:746–749.
5. Shiraki K, Yoshihara N, Sakurai M, et al. Acute hepatitis B in infants born to carrier mother with the antibody to hepatitis B e antigen. J Pediatr 1980; 97:768–770.
6. Slowik MK, Jhaveri R. Hepatitis B and C viruses in infants and young children. Semin Pediatr Infect Dis 2005; 16:296–305.
7. Shneider BL, Gonzalez-Peralta R, Roberts EA. Controversies in the management of pediatric liver disease: hepatitis B, C, and NAFLD: Summary of a single topic conference. Hepatology 2006; 44:1344–1354.
8. McGill DB, Rakela J, Zinsmeister AR, et al. A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology 1990; 99:1396–1400.
9. Van Thiel DH, Gavaler JS, Wright H, et al. Liver biopsy. Its safety and complications as seen at a liver transplant center. Transplantation 1993; 55:1087–1090.
10. de Ledinghen V, Le Bail B, Rebouissoux L, et al. Liver stiffness measurement in children using FibroScan: feasibility study and comparison with Fibrotest, aspartate transaminase to platelets ratio index, and liver biopsy. J Pediatr Gastroenterol Nutr 2007; 45:443–450.
11. Halfon P, Bacq Y, De Muret A, et al. Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C. J Hepatol 2007; 46:395–402.
12. Lebensztejn DM, Skiba E, Sobaniec-Lotowska M, et al. A simple noninvasive index (APRI) predicts advanced liver fibrosis in children with chronic hepatitis B. Hepatology 2005; 41:1434–1435.
13. Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology 2007; 46:912–921.
14. Shin WG, Park SH, Jang MK, et al. Aspartate aminotransferase to platelet ratio index (APRI) can predict liver fibrosis in chronic hepatitis B. Dig Liver Dis 2008; 40:267–274.
15. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38:518–526.
16. Park GJ, Lin BP, Ngu MC, et al. Aspartate aminotransferase: alanine aminotransferase ratio in chronic hepatitis C infection: is it a useful predictor of cirrhosis? J Gastroenterol Hepatol 2000; 15:386–390.
17. Park SY, Kang KH, Park JH, et al. Clinical efficacy of AST/ALT ratio and platelet counts as predictors of degree of fibrosis in HBV infected patients without clinically evident liver cirrhosis. Korean J Gastroenterol 2004; 43:246–251.
18. Giannini E, Botta F, Borro P, et al. Platelet count/spleen diameter ratio: proposal and validation of a non-invasive parameter to predict the presence of oesophageal varices in patients with liver cirrhosis. Gut 2003; 52:1200–1205.
19. Hess CE, Ayers CR, Sandusky WR, et al. Mechanism of dilutional anemia in massive splenomegaly. Blood 1976; 47:629–644.
20. Gomez P, Coca C, Vargas C, et al. Normal reference-intervals for 20 biochemical variables in healthy infants, children, and adolescents. Clin Chem 1984; 30:407–412.
21. Bortolotti F. Treatment of chronic hepatitis B in children. J Hepatol 2003; 39(Suppl 1):S200–S205.
22. Bortolotti F, Guido M. Hepatitis B in children. Hepatology 2007; 45:831, author reply 831.
23. Bortolotti F, Guido M, Zancan L, et al. Long-term outcome of hepatitis C in children. Hepatology 2004; 39:1455–1456.
24. Bortolotti F, Verucchi G, Camma C, et al. Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease. Gastroenterology 2008; 134:1900–1907.
25. Guido M, Bortolotti F. Chronic viral hepatitis in children: any role for the pathologist? Gut 2008; 57:873–877.
26. Resti M, Jara P, Hierro L, et al. Clinical features and progression of perinatally acquired hepatitis C virus infection. J Med Virol 2003; 70:373–377.
27. Zhang HF, Yang XJ, Zhu SS, et al. Pathological changes and clinical manifestations of 1020 children with liver diseases confirmed by biopsy. Hepatobiliary Pancreat Dis Int 2004; 3:395–398.
28. Goodman ZD, Makhlouf HR, Liu L, et al. Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial. Hepatology 2008; 47:836–843.
This article has been cited 1 time(s).
Journal of PediatricsSerum Biomarkers and Transient Elastography as Predictors of Advanced Liver Fibrosis in a United States Cohort: The Boston Children's Hospital ExperienceJournal of Pediatrics
APRI; fibrosis; hepatitis B; hepatitis C; noninvasive markers
© 2010 Lippincott Williams & Wilkins, Inc.